Safety and Effectiveness of TaurusTrio™ Heart Valve System in Patients With Severe Aortic Regurgitation (AR)

A Prospective, Multicenter, Single-group Clinical Study to Evaluate the Safety and Efficacy of Peijia Medical Transcatheter Aortic Valve System in the Treatment of Severe Aortic Valve Regurgitation

To evaluate the safety and effectiveness of the TaurusTrio™ Heart Valve System in a patient population with symptomatic severe AR requiring replacement/repair of their native aortic valve that are at high risk for open surgical aortic valve replacement/repair (SAVR).

Inclusion Criteria:

• Patients who voluntarily participate and sign the informed consent and are able to comply with the entire trial process;

• Age ≥ 18 years;

• Adult subjects with severe AR (Grade ≥ 3) as assessed by echocardiography based on ASE (American Society of Echocardiography) using multiparametric approach with:

  • Jet width ≥ 65% of LVOT
  • Vena contracta width of > 6 mm
  • Holodiastolic flow reversal in proximal abdominal/descending aorta
  • Jet deceleration rate/Pressure half time <200ms
  • AND, For Grade 3:
  • Regurgitant volume ≥ 45-59 ml/beat
  • Regurgitant fraction ≥ 40-49%
  • EROA ≥ 0.2-0.29 cm2
  • OR, For Grade 4:
  • Regurgitant volume ≥ 60 ml/beat
  • Regurgitant fraction≥50%
  • EROA ≥ 0.3 cm2 Note: In cases where not all criteria listed for severe AR are met, the Core Lab will determine severity. Supplemental CMR imaging may be used to substantiate the degree of AR reported by Core Lab on baseline echo when imaging is suboptimal, Doppler parameters are discordant or inconclusive regarding the severity of AR, or when a discrepancy is present between the echo findings and the clinical setting.

• Patients who have symptoms obviously caused by Aortic Regurgitation, such as dyspnea, chest pain, NYHA Class II or higher;

• Patients who are unsuitable for conventional surgery but needs TAVR（It is recommended to refer to the 2020 ACC/AHA Heart Valve Disease Management Guidelines when evaluating the risks of surgical valve surgery），evaluated by the cardiac team (including at least one interventional cardiologist and one cardiovascular surgeon)

• Patient has suitable anatomy to accommodate the insertion and delivery of the JenaValve Trilogy™ Heart Valve System，evaluated by core laboratory;

Exclusion Criteria:

• Congenital uni- or bicuspid aortic valve morphology；
• Previous prosthetic aortic valve (bioprosthesis or mechanical) implant；
• Mitral regurgitation or Tricuspid regurgitation> moderate；
• Clinically significant coronary artery disease (CAD) requiring revascularization within 30 days prior to index procedure, or planned CAD revascularization procedure within 12 months after index procedure；
• Echocardiographic evidence of left ventricular thrombus；
• Endocarditis within 180 days prior to index procedure；
• Hypertrophic cardiomyopathy with or without obstruction；
• Severe pulmonary hypertension (systolic PA pressure >80 mmHg)；
• Severe RV dysfunction as assessed clinically and by echo；
• Severely reduced left ventricular ejection fraction (LVEF <25%)；
• Aortic annular perimeter derived diameter of <21.0 mm or > 28.6 mm or perimeter <66.0 mm or >90 mm (assessed by Multi-Detector CT measurement)；
• Aortic annulus angulation > 70° (assessed by Multi-Detector CT measurement)；
• Straight length of ascending aorta of < 55 mm；
• Significant disease of ascending aorta, including ascending aortic aneurysm ； (defined as maximal luminal diameter of 50 mm or greater) or atheroma (including if thick [>5 mm], protruding or ulcerated)
• Need for urgent or emergent TAVR procedure for any reason；
• Cardiogenic shock or hemodynamic instability requiring inotropic support or ventricular assist device within 30 days prior to index procedure；
• Myocardial infarction < 30 days prior to index procedure；
• Cerebrovascular event (TIA, stroke) < 180 days prior to index procedure；
• Patients with common carotid artery or internal carotid artery or vertebral artery stenosis (>70%)；
• Patients with severe coagulopathy；
• Severe renal insufficiency (GFR < 30 ml/min) at Screening, OR renal disease requiring renal replacement therapy within 180 days prior to index procedure；
• Blood dyscrasias as defined: leukopenia (WBC < 3000/mm³), or thrombocytopenia (platelets < 90,000/µl) or anemia (Men: Hgb < 8.1 g/dl; Women: Hgb < 7.4 g/dl)；
• Active peptic ulcer or upper gastrointestinal bleeding < 90 days prior to index procedure；
• Known allergies to to heparin, aspirin, ticlopidine, Clopidogrel, Nitroglycerin and other drugs，contrast agents, nitinol shape memory alloy, tantalum or porcine products；
• Contraindication to intraoperative transesophageal echocardiography and/or Multi-Detector CT (MDCT) scan；
• Estimated life-expectancy of < 24 months；
• Patient is enrolled in another investigational medical device or drug study which has not completed the required primary endpoint follow-up. (Note: Patients involved in a long-term surveillance phase of another study are eligible for enrollment in this study);
• Other medical, social, or psychological conditions that in the opinion of an Investigator precludes the patient from providing appropriate informed consent;
• Severe dementia (resulting in either inability to provide informed consent for the trial/procedure, prevents independent lifestyle outside of a chronic care facility, or will fundamentally complicate rehabilitation from the procedure or compliance with follow-up assessments);
• Unable to comply with follow-up requirements;